Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

a non-small cell lung cancer protocol in combination with carboplatin and paclitaxel. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...c. 1 TargeGen has announced that a...a multi-center, US-based clinical,trial of TG1013... scheduled at,the 2008 American Society of Hemato...entation are as follows:, Title: ...ble, JAK2-Selective Inhibi...
(Date:12/1/2008)...nce is still the best policy , , ROCHESTER...tudy from Mayo Clinic finds the use of the drug th... hepatitis, an acute inflammation of the liver cau...ts of the study are published in the December issu....org/ ). , , VIDEO ALERT: Additional audio...
(Date:12/1/2008)...c. 1 Vical Incorporated ... $1.0 million milestone payment from Merck & C...Phase I clinical trial of an investigational plasm...e is based on Vical,s DNA gene delivery technology...e (hTERT). hTERT is the subject of separate licens...
(Date:11/27/2008)...ds the majority of acute lymphoblastic leukemia re...he time of diagnosis , , MEMPHIS, Tenn., No... Jude Children,s Research Hospital have identified...f children with acute lymphoblastic leukemia (ALL)...to designing treatments for ALL relapse in childre...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3High pollution linked to poor lung function growth in children in Mexico City 50 1High pollution linked to poor lung function growth in children in Mexico City 50 2Clinical depression linked to abnormal emotional brain circuits 46 1Clinical depression linked to abnormal emotional brain circuits 46 2Clinical depression linked to abnormal emotional brain circuits 46 3HPV vaccine does not appear to be effective for treating pre existing HPV infection 42 1HPV vaccine does not appear to be effective for treating pre existing HPV infection 42 2HPV vaccine does not appear to be effective for treating pre existing HPV infection 42 3New review suggests caution on drugs to raise good cholesterol 38 1New review suggests caution on drugs to raise good cholesterol 38 2New review suggests caution on drugs to raise good cholesterol 38 3
...ESTERSHIRE , England, 21 June 2007, Malvern Instru... users of the company,s,near infrared chemical ima...ok place on 13 June 2007 was hosted by AstraZeneca...of the world,s major,pharmaceutical companies join...program that included oral and poster presentation...
...INGTON, June 20, 2007 /PRNewswire-USNewswire/ -- T...nt Bush on stem cell,veto and executive order: , E... I,m glad you,re here. America is a,nation that le...ative spirit is making possible incredible advance...ses. America is also a,nation founded on the princ...
Other Medicine Technology:Malvern initiates European user group meetings for chemical imaging 2Malvern initiates European user group meetings for chemical imaging 3Remarks by President Bush on Stem Cell Veto and Executive Order 2Remarks by President Bush on Stem Cell Veto and Executive Order 3Remarks by President Bush on Stem Cell Veto and Executive Order 4Remarks by President Bush on Stem Cell Veto and Executive Order 5Remarks by President Bush on Stem Cell Veto and Executive Order 6
(Date:12/1/2008)...t the availability of a portable eight-slice compu...an significantly increase the number of stroke vic...nt. Results of the study, conducted at North Shore...ss., will be presented today at the annual meeting...A). , "The hospital,s acquisition of a portable...
(Date:12/1/2008)...es with President on U.S. HIV/AIDS Initiatives and...ack Civil Forum on Global Health , , WASHIN...ush was honored on the 20th anniversary of World A...ACE" given by Dr. Rick Warren on behalf of the Glo...rum on Global Health. The award, given in recogni...
(Date:12/1/2008)...e/ -- In the face of one of the most,severe econo...Health Board of,Directors has approved an investm... the Sutter Health Retirement Plan. Employee pensi...cks and bonds, have been among the biggest,casual...onservatively,invested, the Sutter Health Retirem...
(Date:12/1/2008)...all/ -- ViroPharma Incorporated,(Nasdaq: VPHM )...lemental,Biologics License Application (sBLA) to ...inryze(TM) C1 Inhibitor (human) as a treatment for... The sBLA is based on a re-analysis and resu...atment study of Cinryze and interim data from an o...
Breaking Medicine News(10 mins):Health News:Portable CT increases chance of stroke survival and recovery 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5
... the death of 200 cattle due to anthrax in the las...pread the deadly disease to the cattle in the prov...ting due to severe shortage of vaccines. Infact, t...g vaccines, should be the number one priority in t...
...issue of Canadian Journal Emergency Medicine, sug...ted to over 3% (40,000) of 1.2 million emergency v.... // The study Researchers at the Toronto-based I...es (ICES) looked at the gunshots and knife wounds ...
...clinics in China have been asked to be watchful ab...le cases. //The Ministry of Health has also reques... in diarrhea cases. As Norovirus infections are h...ercise caution while eating in restaurants and hot...
... head and neck tumor cells that indicates which ce...e finding is the first evidence of cancer stem cel...e the small number of cancer cells that replicate ...ieve current cancer treatments sometimes fail beca...
Other Medicine News:Health News:Stem Cell Marker Identified in Head and Neck Cancer 2
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies.
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels.
The new Multichamber one-piece baseplate is designed specifically for Urostomates; it is significantly thicker than the current Assura, allowing it to resist urine erosion for longer. The product is
...t for the screening of factor-V-related APC resist...test for the factor V:Q506 mutation is obtained by...-DEF Plasma bioreagent. The test design makes it p...omozygous factor V genotypes. It also allows for a...
Medicine Products: